DW Healthcare Partners lll, LP (‘DWHP’), a private equity firm focused exclusively on the healthcare industry, announced today it has invested in Z-Medica Corporation (‘Z-Medica’). Founded in 2002, Z-Medica is a leading medical device company that develops, manufactures and markets innovative hemostatic agents including the QuikClot family of products that rapidly enhance the body’s natural coagulation process. Financial terms of the transaction were not disclosed.
‘ZMedica is an incredibly exciting company with exceptionally innovative products with applications to control bleeding. We look forward to helping further the mission of providing unique products that improve patient outcomes and ultimately save lives’ said Doug Schillinger, a Managing Director with DWHP. ‘Co-founders Bart Gullong and Frank Hursey built a market leader with an impressive management team which will be led going forward by Larry Hicks. Larry is a seasoned healthcare executive with decades of experience building high growth, progressive medical product companies.’
About Z-Medica Corporation
Z-Medica Corporation, based in Wallingford, CT, is a medical device company developing innovative hemostatic agents. Their mission is to develop fast acting, easy to use, hemostasis products that control bleeding, enabling their customers to save lives and improve patient outcomes. The company manufactures and markets its QuikClot family of hemostasis products for use by healthcare professionals, first responders, law enforcement officers and the military.
For more information, please visit: http://www.z-medical.com
ABOUT DW HEALTHCARE PARTNERS
DW Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. The firm manages over $800 million in committed capital and invests in profitable healthcare companies with proven management teams.
DW Healthcare Partners is led by seasoned healthcare executives with more than 110 years of combined industry experience. The firm provides the capital, strategic guidance, and acquisition expertise to help mid-to-late-stage companies realize their potential for growth.
